13F reference period
Q2 2026
Security Snapshot
Camp4 Therapeutics Corp - Common Stock (CAMP) Institutional Ownership
CUSIP: 13463J101
13F Institutional Holders and Ownership History from Q4 2024 to Q3 2026
Institutions Reporting
61
Shares (Excl. Options)
41.68M
Full value: 41,680,926 · shares · 30 Jun 2026Price
$4.37
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CAMP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 41,680,926
- Total 13F value
- $182,164,650
- Portfolio coverage rank
- 0%
- Share change
- +1,888,640
- Value change
- +$8,234,195
- Number of holders
- 61
- Shares outstanding
- 64,435,606
- SEC-reported price per share
- $4.04
- Insider filing price
- $4.04
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CAMP - Camp4 Therapeutics Corp - Common Stock is tracked under CUSIP 13463J101.
- 61 institutions reported positions in Q2 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 46 to 61 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$175.51M
Full value: $175,508,361 · USD · 31 Mar 2026.$182.16M
Full value: $182,164,650 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 61 institutions filings for Q2 2026.
Security key
13463J101
13F reference period
Q2 2026
13F holders
61
13D/G owners
12
CIK / CUSIP context first
Open Q2 2026 holders
CAMP full holder history
Camp4 Therapeutics Corp SEC filings
Camp4 Therapeutics Corp company facts
Camp4 Therapeutics Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 13463J101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
CAMP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| 5AM Ventures VI, L.P. | 9.9% | 0% | $21,816,608 | +$224,663 | 6,379,125 | +1% | Andrew J. Schwab | 27 Aug 2026 |
| JANUS HENDERSON GROUP PLC | 12% | $37,908,892 | 6,307,636 | JANUS HENDERSON GROUP PLC | 31 Dec 2025 | |||
| FMR LLC | 9.5% | +40% | $28,968,451 | +$10,440,496 | 4,918,243 | +56% | FMR LLC | 31 Dec 2025 |
| Coastlands Capital LP | 10% | $21,452,710 | 4,886,722 | Coastlands Capital LP | 10 Sep 2025 | |||
| Polaris Management Co. VII, L.L.C. | 6.3% | -26% | $13,448,298 | 3,932,251 | 0% | Amir Nashat | 13 Aug 2026 | |
| Vivo Opportunity Fund Holdings, L.P. | 7.4% | -2.5% | $23,373,365 | +$1,788,900 | 3,856,991 | +8.3% | Vivo Opportunity Fund Holdings, L.P. | 31 Dec 2025 |
| Trails Edge Capital Partners, LP | 6% | $17,057,862 | 3,790,636 | Trails Edge Capital Partners, LP | 03 Aug 2026 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 5% | -1.6% | $11,659,936 | -$186,030 | 2,591,097 | -1.6% | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 |
| Enavate Sciences GP, LLC | 4.8% | -20% | $10,955,517 | -$2,773,593 | 2,495,562 | -20% | Enavate Sciences GP, LLC | 09 Mar 2026 |
| Northpond Ventures II, LP | 4.8% | $6,714,732 | 2,238,244 | Michael P. Rubin | 30 Sep 2025 | |||
| AH Bio Fund I, L.P. | 4.5% | $6,376,017 | 2,125,339 | Marc L. Andreessen | 30 Sep 2025 | |||
| HARBOURVEST PARTNERS LLC | 2.7% | -60% | $3,536,015 | 1,271,948 | 0% | HarbourVest Partners L.P. | 30 Sep 2025 |
As of 30 Jun 2026,
61
institutional investors reported holding
shares of
Camp4 Therapeutics Corp - Common Stock (CAMP).
This represents
65%
of the company’s total
outstanding shares.
41.68M
Full value: 41,680,926 · shares · 30 Jun 202664.44M
Full value: 64,435,606 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
64%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 9.8% | 6,307,636 | 0% | 0.01% | $27,581,036 |
| 5AM Venture Management, LLC | 9.1% | 5,869,091 | 0% | 8.9% | $25,647,928 |
| FMR LLC | 7.6% | 4,904,339 | -0.59% | 0% | $21,431,962 |
| Vivo Capital, LLC | 6.6% | 4,246,568 | 0% | 1.7% | $18,557,502 |
| Balyasny Asset Management L.P. | 4% | 2,575,724 | -2.2% | 0.02% | $11,255,914 |
| a16z Capital Management, L.L.C. | 3.3% | 2,125,339 | 0% | 0.07% | $9,287,731 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3% | 1,960,784 | 0% | 0.01% | $8,568,626 |
| Trails Edge Capital Partners, LP | 3% | 1,932,937 | -0.34% | 1.3% | $8,446,935 |
| BlackRock, Inc. | 2.6% | 1,644,134 | +260% | 0% | $7,184,865 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.4% | 1,533,489 | -0.08% | 0% | $6,701,347 |
| ENAVATE SCIENCES GP, LLC | 2.2% | 1,425,541 | -35% | 1.8% | $6,229,614 |
| Stonepine Capital Management, LLC | 2.2% | 1,389,622 | 0% | 4.6% | $6,072,648 |
| HarbourVest Partners LLC | 2% | 1,271,948 | 0% | 3.3% | $5,558,413 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 795,651 | +108% | 0% | $3,477,876 |
| SummitTX Capital, L.P. | 1.1% | 725,160 | +114% | 0.08% | $3,168,949 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1% | 653,594 | 0% | 0.32% | $2,856,206 |
| STATE STREET CORP | 0.56% | 362,300 | +147% | 0% | $1,583,251 |
| NORTHERN TRUST CORP | 0.39% | 248,673 | +252% | 0% | $1,086,701 |
| GOLDMAN SACHS GROUP INC | 0.37% | 241,393 | +208% | 0% | $1,054,887 |
| VANGUARD FIDUCIARY TRUST CO | 0.35% | 226,074 | +16% | 0% | $987,943 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.34% | 220,717 | 0% | $964,533 | |
| Birchview Capital, LP | 0.19% | 120,000 | 0.25% | $524,400 | |
| TWO SIGMA INVESTMENTS, LP | 0.16% | 104,610 | -3.9% | 0% | $457,146 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.15% | 96,660 | +383% | 0% | $422,404 |
| Bank of New York Mellon Corp | 0.13% | 83,421 | +346% | 0% | $364,550 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Headline period
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,453 | $5,871 | -$134,388 | $4.04 | 5 |
| 2026 Q2 | 41,680,926 | $182,164,650 | +$8,234,195 | $4.37 | 61 |
| 2026 Q1 | 39,782,653 | $175,508,361 | +$5,383,258 | $4.41 | 46 |
| 2025 Q4 | 38,247,378 | $234,599,194 | +$51,453,984 | $6.13 | 39 |
| 2025 Q3 | 28,210,083 | $84,630,390 | +$49,505,803 | $3.00 | 28 |
| 2025 Q2 | 11,744,129 | $17,029,220 | -$3,217,598 | $1.45 | 28 |
| 2025 Q1 | 12,677,488 | $50,710,355 | -$1,002,366 | $4.00 | 39 |
| 2024 Q4 | 12,854,057 | $67,096,861 | +$47,332,167 | $5.22 | 36 |